Organon & Co.
NYSEOrganon & Co. arrives at its April 30 Q1 print riding one of the most dramatic recoveries in the pharmaceutical space — up 125% in a month and 42% in the past week alone — yet the analyst community remains firmly in the bearish camp. Options positioning captures the most striking feature of the setup: traders have sharply abandoned downside protection ahead of the earnings date. The…
Snapshot as of 9 May 2026
Organon & Co. arrives at its April 30 Q1 print riding one of the most dramatic recoveries in the pharmaceutical space — up 125% in a month and 42% in the past week alone — yet the analyst community remains firmly in…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for OGN — free to start on ORTEX.
Sign up for free →Open OGN on ORTEX